New NSAID targets and derivatives for colorectal cancer chemoprevention

Recent Results in Cancer Research

Volumn 191, Issue , 2013, Pages 105-120

  Tinsley, Heather N ^a   Grizzle, William E ^b   Abadi, Ashraf ^c   Keeton, Adam ^d   Zhu, Bing ^d   Xi, Yaguang ^d   Piazza, Gary A ^d  

^a UNIVERSITY OF MONTEVALLO   (United States)

^b University of Alabama at Birmingham   (United States)

^c German University in Cairo   (Egypt)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CHLOROANILINO) 4 PHENYLPHTHALAZINE; 2,5 DIMETHYL CELECOXIB; ACETYLSALICYLIC ACID; CELECOXIB; CYCLIC GMP PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE INHIBITOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; FENOPROFEN; FLUFENAMIC ACID; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; MECLOFENAMIC ACID; MICRORNA; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIROXICAM; REACTIVE OXYGEN METABOLITE; ROFECOXIB; SALICYLATE SODIUM; SILDENAFIL; SULINDAC SULFIDE; SURVIVIN; TOLFENAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROQUANYLIN; VALDECOXIB;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL TUMOR; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84867085932     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-30331-9_6     Document Type: Review

References (92)

1. Alberts DS et al (1995) Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase? J Cell Biochem Suppl 22:18-23
2. Altieri DC (2003a) Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 5:447-452
3. Altieri DC (2003b) Survivin and apoptosis control. Adv Cancer Res 88:31-52
4. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8):917-921
5. Arber N et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885-895
6. Baek SJ, Horowitz JM, Eling TE (2001a) Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 276(36):33384-33392
7. Baek SJ et al (2001b) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59(4):901-908
8. Baek SJ et al (2002) Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): Inhibition of cyclooxygenase and induction ofNSAID-activated gene. J Pharmacol Exp Ther 301(3):1126-1131
9. Baron JA et al (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131(6):1674-1682
10. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75(4):725-748
11. Bertagnolli MM et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873-884
12. Carmell MA et al (2002) The Argonaute family: Tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 16(21):2733-2742
13. Carter CA, Ip MM, Ip C (1989)Acomparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 10(8):1369-1374
14. Chakraborti AK et al (2010) Progress in COX-2 inhibitors: A journey so far. Curr Med Chem 17(15):1563-1593
15. Chan TA (2002) Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3(3):166-174
16. de Mello MC, Bayer BM, Beaven MA (1980) Evidence that prostaglandins do not have a role in the cytostatic action of anti-inflammatory drugs. Biochem Pharmacol 29(3):311-318
17. DuBois RN et al (1998) The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 19(1):49-53
18. Eberhart CE et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4):1183-1188
19. Elder DJ et al (1997) Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: Independence from COX-2 protein expression. Clin Cancer Res 3(10):1679-1683
20. Erickson BA et al (1999) The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81(1):101-107
21. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6(4):259-269
22. Frein D et al (2005) Redox regulation: A new challenge for pharmacology. Biochem Pharmacol 70(6):811-823
23. Fujita T et al (1998) Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58(21):4823-4826
24. Genestra M (2007) Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell Signal 19(9):1807-1819
25. Giardiello FM et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328(18):1313-1316
26. Grosch S et al (2001) COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. Faseb J 15(14):2742-2744
27. Halliwell B (2007) Oxidative stress and cancer: have we moved forward? Biochem J 401(1):1-11
28. Hanif R et al (1996) Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52(2):237-245
29. Harris RE (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17(2):55-67
30. Hoffman WH et al (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277(5):3247-3257
31. Huang GL et al (2009) Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep 21(3):673-679
32. Huang L et al (2010) Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: A redox/polyamine-dependent effect. Carcinogenesis 31(11):1982-1990
33. Kalgutkar AS et al (2000) Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors. J Med Chem 43(15):2860-2870
34. Kalgutkar AS et al (2002) Amide derivatives of meclofenamic acid as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem Lett 12(4):521-524
35. KardoshAet al (2005)Multitarget inhibition of drug- resistantmultiplemyeloma cell lines by dimethylcelecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib. Blood 106(13):4330-4338
36. Kashfi K, Rigas B (2005) Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 33(Pt 4):724-727
37. Kashfi K, Rigas B (2007) The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun 358(4):1096-1101
38. Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239-267
39. Konduri S et al (2009) Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533-542
40. Kusuhara H et al (1998) Induction of apoptotic DNA fragmentation by nonsteroidal antiinflammatory drugs in cultured rat gastric mucosal cells. Eur J Pharmacol 360(2-3):273-280
41. Lefebvre AM et al (1998) Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6 J-APCMin/+ mice. Nat Med 4(9):1053-1057
42. Lehmann JM et al (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272(6):3406-3410
43. Li F (2005) Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92(2):212-216
44. Lincoln TM, Cornwell TL (1993) Intracellular cyclic GMP receptor proteins. Faseb J 7(2):328-338
45. Ljungdahl S, Shoshan MC, Linder S (1997) Inhibition of the growth of 12 V-ras-transformed rat fibroblasts by acetylsalicylic acid correlates with inhibition of NF-kappa B. Anticancer Drugs 8(1):62-66
46. Ma L, Teruya-Feldstein J, Weinberg RA (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449(7163):682-688
47. Ma L et al (2010a) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28(4):341-347
48. Ma L et al (2010b) MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12(3):247-256
49. Mackenzie GG et al (2010) Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice. Gastroenterology 139(4):1320-1332
50. Mueller E et al (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1(3):465-470
51. Nakajima G et al (2006) Non-coding microRNAs hsa-let-7 g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3(5):317-324
52. Oshima M et al (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87(5):803-809
53. Piazza GA et al (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55(14):3110-3116
54. Piazza GA et al (1997a) Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 57(12):2452-2459
55. Piazza GA et al (1997b) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57(14):2909-2915
56. Piazza GA et al (2009) A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila Pa) 2(6):572-580
57. Pyrko P et al (2006) Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2- inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5:19
58. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18(49):6938-6947
59. Rigas B, Kashfi K (2004) Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 10(7):324-330
60. Rigas B, Kozoni V (2008) The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin). Int J Oncol 32(1):97-100
61. Rigas B, Williams JL (2008) NO-donating NSAIDs and cancer: An overview with a note on whether NO is required for their action. Nitric Oxide 19(2):199-204
62. Saez E et al (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4(9):1058-1061
63. Sawaoka H et al (1998) Effects of NSAIDs on proliferation of gastric cancer cells in vitro: Possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 27(Suppl 1):S47 - S52
64. Schwenger P et al (1998) Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol 18(1):78-84
65. Shailubhai K et al (2000) Uroguanylin treatment suppresses polyp formation in the Apc(Min/+) mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 60(18):5151-5157
66. Shiff SJ, Rigas B (1999) The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190(4):445-450
67. Silvola J et al (1982) Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity. Agents Actions 12(4):516-520
68. Soh JW et al (2000) Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin Cancer Res 6(10):4136-4141
69. Soh JW et al (2008) Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog 47(7):519-525
70. Song B et al (2010) MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res 29:29
71. Sonnenburg WK, Beavo JA (1994) Cyclic GMP and regulation of cyclic nucleotide hydrolysis. Adv Pharmacol 26:87-114
72. Steinbach G et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342(26):1946-1952
73. Sun Y et al (2011) Oxidative stress mediates through apoptosis the anticancer effect of phospho-NSAIDs: Implications for the role of oxidative stress in the action of anticancer agents. J Pharmacol Exp Ther 338(3):775-783
74. Thompson WJ et al (2000) Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60(13):3338-3342
75. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252-266
76. Tinsley HN et al (2009) Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 8(12):3331-3340
77. Tinsley HN et al (2010) Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 3(10):1303-1313
78. Tinsley HN et al (2011) Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/{beta}-Catenin- Mediated Transcription in Human Breast Tumor Cells. Cancer Prev Res (Phila) 4(8):1275-1284
79. Toyokuni S et al (1995) Persistent oxidative stress in cancer. FEBS Lett 358(1):1-3
80. Tsujii M et al (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93(5):705-716
81. Vane JR, Botting RM (1998) Mechanism of action of antiinflammatory drugs. Int J Tissue React 20(1):3-15
82. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120
83. Warner TD et al (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci U S A 96(13):7563-7568
84. Williams JL et al (2004) NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 313(3):784-788
85. Xi Y et al (2006) Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2: 113-121
86. Xie G et al (2011) Phospho-ibuprofen (MDC-917) is a novel agent against colon cancer: Efficacy, metabolism, and pharmacokinetics in mouse models. J Pharmacol Exp Ther 337(3):876-886
87. Yeh RK et al (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: A general pharmacological property? Biochem Pharmacol 67(12):2197-2205
88. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396(6706):77-80
89. Yu Z et al (2010) MicroRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 107(18):8231-8236
90. Zaffaroni N, Pennati M, Daidone MG (2005) Survivin as a target for new anticancer interventions. J Cell Mol Med 9(2):360-372
91. Zhu B et al (2005) Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94(2):336-350
92. Zhu S et al (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18(3):350-359